We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Thanet CCG area.
Executive summary of the abdominal aortic aneurysm (AAA) quality assurance (QA) visit to Thames Valley held on 3 October 2019.
Executive summary of quality assurance (QA) visit to North London held on 28 February 2019.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Lambeth CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Erewash CCG area.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in the Basildon and Brentwood CCG area.
Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.
The MHRA is reviewing the evidence relating to the very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with medicines containing pseudoephedrine
Government removes ban on UK-sourced blood plasma for the manufacture of immunoglobulins.
We want to remind healthcare professionals that use of systemic (oral and injectable) NSAIDs such as ibuprofen, naproxen, and diclofenac is contraindicated in the last trimester of pregnancy (after 28 weeks of pregnancy).
Lupin Healthcare (UK) Limited has informed us that the affected batches of Simvastatin tablets have been packaged with a version of patient information leaflet that does not include the most up to date safety information.
Reminder of the updated guidance on blood and blood products for animal treatment.
Before initiating systemic vascular endothelial growth factor (VEGF) pathway inhibitors, carefully consider the risk of aneurysm and artery dissection in patients with risk factors. In patients who receive a systemic VEGF pathway inhibitor, reduce as far as possible any modifiable...
Summary list of field safety notices (FSNs) from medical device manufacturers from 7 to 11 June 2021.
The MHRA has published advice for patients and healthcare professionals
Available evidence shows that the risk of blood vessel blockage with ponatinib is likely to be dose-dependent, however the data are insufficient to recommend reducing the ponatinib dose.
Surveyors from the Maritime and Coastguard Agency are to carry out unannounced inspections of fishing vessels across the UK.
New rules which will bring the safety of older passenger ships in line with modern standards fit for the 21st century are now in force for the UK.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).